A new research study published out of the UK in April 2023 in Hypertension found that more than half of all preeclampsia cases which occur during weeks 37-42 of pregnancy (“at-term”) may be prevented with timed birth.
Screening for preeclampsia is a routine part of prenatal care, but there are limited treatment options when it occurs, besides delivery of the baby and the placenta regardless of the gestational age of the baby. Preterm deliver is often considered an option for women who begin displaying serious signs and symptoms of preeclampsia during weeks 20-36; however, the majority of preeclampsia cases occur at-term (weeks 37-42 of pregnancy). The study used a risk assessment model to assess whether planned, timed birth strategies prior to preeclampsia’s onset, could help prevent preeclampsia.
Timed birth strategies, including induced labor and Cesarean (c-section) deliveries that are planned in advance, are already widely used for other maternal health concerns. They are seldom used, however, as an intervention for preventing at-term preeclampsia.
“Timed birth is achievable in many hospitals or health centers,” said lead study author Laura A. Magee, M.D., a professor of women’s health at King’s College in London, “so our proposed approach to prevent at-term preeclampsia has huge potential for global good in maternity care.”
Researchers examined more than 10 years of health records for nearly 90,000 pregnancies at two hospitals (King’s College Hospital, London and Medway Maritime Hospital, Gillingham) in the United Kingdom. There were 57,131 pregnancies with health records at 11 to 13 weeks (between 2006 and 2017), in which there were 1,138 cases of at-term preeclampsia; and 29,035 pregnancies at 35 to 36 weeks (between 2016 and 2018), in which there were 619 cases of at-term preeclampsia. In the analysis, researchers evaluated risk of preeclampsia and potential benefits of timed birth for both groups with standard clinical criteria for preeclampsia and a risk prediction model (computer program that predicts risk of preeclampsia based on various individual factors, such as maternal history, blood pressure, ultrasound and blood tests).
There were limitations to the study, which is important to consider when examining its potential as an intervention in the United States. The study was designed to examine options through risk modeling – no interventions were offered to the participants. The study also did not examine rates of postpartum preeclampsia. Though this represented a large data set, the majority of women examined were in their early 30s, self-identified as white, and had a higher body mass index (BMI). On average, women included in the study delivered at 40-weeks, and two-thirds of all participants experienced spontaneous onset of labor. About one-fourth of the women included in the analysis had Cesarean deliveries. Only 3.9% reported a family history of preeclampsia.
While this study will not change current care practices, it does open the way for further research studies which can examine the use of timed delivery to prevent preeclampsia.
Your story is needed to improve outcomes for moms like you. Add your voice to critical preeclampsia research to ensure that every story is heard.
The Preeclampsia Foundation's published research results.
Frequently asked questions about the Preeclampsia Registry, a patient-driven registry and biobank.
The Preeclampsia Foundation offers research funding, study recruitment, and other patient engagement services to researchers.
We provide research grant funding to advance progress towards detection, prevention, or treatment of preeclampsia, HELLP syndrome, and other hypertensive disorders of pregnancy.
May 19, 2023 – NEW YORK – Thermo Fisher Scientific announced on Friday, May 19 that it has obtained clearance from the US Food and Drug Administration for two assays to assess risk of...
Long-term neurodevelopmental follow-up of children exposed to pravastatin in utero If given in early pregnancy pravastatin, (a drug used to lower cholesterol) may decrease the risk of developing pree...
Ionizable Lipid Nanoparticles for In Vivo mRNA Delivery to the Placenta during Pregnancy (a rat model) Currently the only treatment for preeclampsia starts with delivery of the baby and the placenta....
The nuMom2b study – short for “Nulliparous* Pregnancy Outcomes Study: Monitoring Mothers-To-Be” – is a prospective study that enrolled over 10,000 first time pregnant women acr...
Current Status and Prospects of the Single-Cell Sequencing Technologies for Revealing the Pathogenesis of Pregnancy-Associated Disorders The adult human body is made up of about 100 trillion cells. I...